

MOREPEN

Date: 09/11/2026

To,

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Symbol: MOREPENLAB

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Scrip Code: 500288

Sub.: Press Release – 'Morepen enters U.S. prescription generics market, building on its established API strengths'

Dear Sir/ Madam,

Please find enclosed press release with the title 'Morepen enters U.S. prescription generics market, building on its established API strengths'.

This is for your information and dissemination on your website.

Thanking you,

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava
Digitally signed by Vipul Kumar Srivastava
Date: 2026.11.09 08:26:06 +05'30'

Vipul Kumar Srivastava
Company Secretary
F-12148

Encl.: a/a

Morepen Laboratories Limited
CIN NO. L24231 HP1984PLC006028
Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com



Morepen Enters U.S. Prescription Generics Market, Building on Its Established API Strengths

Desloratadine Tablets launch complements Morepen's broader API, R&D and CDMO growth strategy

New Delhi | 9 November 2026

Morepen Laboratories Limited announced the launch of its first prescription (Rx) generic product, **Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs,** for distribution in the U.S. market. The initiative is being undertaken through its wholly owned U.S. arm, Morepen Bio Inc.

Morepen has been supplying **Desloratadine API** to the U.S. market for many years. Building on this established API position, the latest launch extends the company's participation further along the pharmaceutical value chain into finished-dosage medicines and U.S. distribution.

Sanjay Suri, Managing Director, Morepen Laboratories Limited, said, "Our long-standing API relationships in regulated markets provide a strong foundation for Morepen's next phase of growth. Alongside our expanding CDMO business, we are selectively extending our capabilities into finished-dosage development and U.S. distribution. This reflects our strategy to build a more integrated, R&D-led pharmaceutical business with sustainable, long-term growth opportunities."

The prescription generics expansion follows Morepen's earlier U.S. OTC product introductions. Separately, the company has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Phosphate Tablets USP, 25 mg, 50 mg and 100 mg. This milestone demonstrates Morepen's growing capabilities in formulation development, analytical science and regulatory filings. The application is currently under regulatory review.

Looking ahead, Morepen intends to pursue additional U.S. prescription generic filings and distribution opportunities where its established API and pharmaceutical R&D capabilities provide a competitive advantage. The company may also evaluate selected opportunities in high-potency APIs (HPAPIs) and oncology, subject to development feasibility, regulatory requirements and market conditions.

About Morepen Laboratories Limited

Morepen Laboratories Limited is a publicly listed Indian pharmaceutical and healthcare company with businesses spanning active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) services, formulations and healthcare products. The company serves customers across domestic and international markets.

Media Contacts

Morepen Laboratories Limited
Rajas Suri
Email: rajas.suri@morepen.com

Propel Communications
Girish Singhal
Email: propelpr.com@gmail.com
Mobile: +91 9810206244